ADP is in a strong financial position. At the end of fiscal 2024, the balance sheet was fairly conservative with debt/EBITDA of only 0.6 times. We expect ADP's annual operating income will comfortably ...
Expanded partnership highlights the parties' emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med's expertise in the development of 212 Pb-based TAT and vast proprietary supply ...
Correcting & Replacing: Y-mAbs Therapeutics, Inc. is re-issuing in entirety its press release, originally issued on January 10, 2025 at 7:05 a.m. ET, to correct a scrivener's error in the presentation ...
Novel Self-Assembly DisAssembly Pre-targeted Radioimmunotherapy (“SADA PRIT”) platform designed to improve upon traditional radioimmunotherapy by delivering high therapeutic dose while minimizing ...